Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price

Enliven Therapeutics (NASDAQ:ELVN) had its price objective upped by Robert W. Baird from $32.00 to $40.00 in a report published on Friday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN opened at $24.90 on Friday. The firm has a 50-day moving average price of $26.28 and a two-hundred day moving average price of $24.02. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -12.99 and a beta of 1.08. Enliven Therapeutics has a 52 week low of $9.80 and a 52 week high of $30.03.

Insider Transactions at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 12,000 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $22.49, for a total value of $269,880.00. Following the completion of the sale, the insider now owns 1,077,936 shares of the company’s stock, valued at $24,242,780.64. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Benjamin Hohl sold 2,000 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $25.33, for a total transaction of $50,660.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 152,195 shares of company stock worth $4,091,454. Insiders own 29.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC boosted its stake in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Enliven Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after buying an additional 3,559 shares during the last quarter. EntryPoint Capital LLC bought a new position in Enliven Therapeutics during the 1st quarter valued at about $167,000. SG Americas Securities LLC bought a new stake in shares of Enliven Therapeutics in the third quarter worth approximately $256,000. Finally, Verition Fund Management LLC purchased a new position in shares of Enliven Therapeutics during the third quarter valued at approximately $271,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.